The Phase 3 ASCEND study investigating natalizumab in the treatment of secondary progressive multiple sclerosis (SPMS) did not achieve its ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments Trader Talk Trading Halts

Leerink Partners Remains Bullish on Biogen (BIIB) Following 3Q Earnings Results October 21, 2015 1:42 PM Cowen Remains Bullish as Biogen (BIIB) Reports 3Q EPS Beat October 21, 2015 1:36 PM Biogen to cut 11 percent of staff, cancel some drug programs; stock jumpsOctober 21, 2015 7:45 AM Biogen (BIIB) will resume trading at 8:00am ETOctober 21, 2015 7:40 AM Form 8-K BIOGEN INC. For: Oct 21October 21, 2015 7:33 AM Biogen (BIIB) Tops Q3 EPS by 68c; Announces Corp. Restructuring; Boosts FY15 EPS OutlookOctober 21, 2015 7:31 AM Biogen Reports Top-Line Results from Phase 3 Study Evaluating Natalizumab in Secondary Progressive MSOctober 21, 2015 7:31 AM Biogen Third Quarter 2015 Revenues Increase 11% to $2.8 Billion; Company Raises 2015 Full Year GuidanceOctober 21, 2015 7:30 AM Biogen (BIIB) Halted, News PendingOctober 21, 2015 7:25 AM